BackgroundKLOTHO-VS heterozygosity (KL-VSHET) and soluble α-Klotho (sαKl) protein interfere with Alzheimer's disease (AD) pathophysiology, but the specific relationships remain unclear. This study explored these associations across the AD continuum, focusing on core AD biomarkers and markers of neurodegeneration, neuroinflammation, and synaptic dysfunction.ObjectiveWe investigated whether 1) KL-VSHET is associated with lower AD biomarker burden (Aβ42, Aβ42/40 ratio, P-tau181, T-tau) and neurodegeneration (NfL); 2) sαKl relates to AD biomarkers, neurodegeneration (NfL), neuroinflammation (GFAP), and synaptic dysfunction (Ng); 3) associations vary by APOE ε4 status and clinical subgroup.MethodsParticipants (n = 223) were categorized as cognitively healthy (n = 38), aMCI-AD (n = 94), and AD dementia (n = 91). KLOTHO genotyping was available for 128 participants; 138 had cerebrospinal fluid (CSF) and serum sαKl measurements; and 42 had both. Multiple linear regression evaluated associations between KL-VSHET, sαKl levels, and biomarkers, stratified by APOE ε4 status and clinical subgroup.ResultsOverall, the associations between KL-VSHET and higher CSF Aβ42 and Aβ42/40 ratio were non-significant (ps ≥ 0.059) except when restricted to APOE ε4 carriers only (β = 0.11, p = 0.008 and β = 0.16, p = 0.033, respectively). Within clinical subgroups, KL-VSHET was positively associated with Aβ42/40 ratio only in aMCI-AD (β = 0.23, p = 0.034). No significant associations were observed between KL-VSHET and tau biomarkers or NfL. For sαKl, associations with biomarkers were non-significant except for a negative association of serum sαKl with P-tau181 in aMCI-AD (β = -0.25, p = 0.036) and a positive association with Aβ42/40 ratio in APOE ε4 non-carriers (β = 0.24 p = 0.047).ConclusionsKL-VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.

Department of Clinical Biochemistry Hematology and Immunology Homolka Hospital Prague Czech Republic

Edson College of Nursing and Health Innovation Arizona State University Phoenix AZ USA

Memory Clinic Department of Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

See more in PubMed

Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med 1996; 47: 387–400. PubMed

Cook NR, Driscoll I, Gallagher CL, et al. Relationships between KLOTHO and APOE4-associated β-amyloid and tau alterations across AD continuum. Alzheimers Dement 2023; 19: e075730.

Driscoll I, Ma Y, Lose SR, et al. AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes. Alzheimers Dement (Amst) 2022; 14: 1–8. PubMed PMC

Grøntvedt GR, Sando SB, Lauridsen C, et al. Association of Klotho protein levels and KL-VS heterozygosity with Alzheimer disease and amyloid and tau burden. JAMA Netw Open 2022; 5: e2243232. PubMed PMC

Ali M, Sung YJ, Wang F, et al. Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS One 2022; 17: e0267298. PubMed PMC

Neitzel J, Franzmeier N, Rubinski A, et al. KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease. Nat Commun 2021; 12: 3825. PubMed PMC

Belloy ME, Eger SJ, Le Guen Y, et al. KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers. Neurobiol Aging 2021; 101: 123–129. PubMed PMC

Belloy ME, Napolioni V, Han SS, et al. Association of Klotho -VS heterozygosity with risk of Alzheimer disease in individuals who carry APOE4. JAMA Neurol 2020; 77: 849–862. PubMed PMC

Eger SJ, Belloy ME, Guen YL, et al. Klotho-VS decreases probability of amyloid pet positivity in APOE4+controls. Alzheimers Dement 2020; 16: 2–4.

Erickson CM, Schultz SA, Oh JM, et al. KLOTHO Heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology 2019; 92: E1878–E1889. PubMed PMC

Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261: 921–923. PubMed

Driscoll I, Ma Y, Gallagher CL, et al. Age-related tau burden and cognitive deficits are attenuated in Klotho KL-vs heterozygotes. J Alzheimers Dis 2021; 79: 1297–1305. PubMed PMC

Driscoll IF, Lose S, Ma Y, et al. KLOTHO KL-VS heterozygosity is associated with diminished age-related neuroinflammation, neurodegeneration, and synaptic dysfunction in older cognitively unimpaired adults. Alzheimers Dement 2024; 20: 5347–5356. PubMed PMC

Gaitán JM, DB D, Okonkwo OC. Circulating klotho is elevated in cerebrospinal fluid, but not serum, among KLOTHO KL-VS allele carriers at risk for Alzheimer’s disease. Alzheimers Dement 2021; 17: e058612.

Yokoyama JS, Marx G, Brown JA, et al. Systemic klotho is associated with KLOTHO variation and predicts intrinsic cortical connectivity in healthy human aging. Brain Imaging Behav 2017; 11: 391–400. PubMed PMC

Dubal DB, Yokoyama JS, Zhu L, et al. Life extension factor Klotho enhances cognition. Cell Rep 2014; 7: 1065–1076. PubMed PMC

Kuro-O M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45–51. PubMed

Xu Y, Sun Z. Molecular basis of klotho: from gene to function in aging. Endocr Rev 2015; 36: 174–193. PubMed PMC

Sedighi M, Baluchnejadmojarad T, Afshin-Majd S, et al. Anti-aging Klotho protects SH-SY5Y cells against amyloid β1-42 meurotoxicity: involvement of Wnt1/pCREB/Nrf2/HO-1 signaling. J Mol Neurosci 2021; 71: 19–27. PubMed

Zeldich E, Chen CD, Colvin TA, et al. The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J Biol Chem 2014; 289: 24700–24715. PubMed PMC

Li D, Jing D, Liu Z, et al. Enhanced expression of secreted α-klotho in the hippocampus alters nesting behavior and memory formation in mice. Front Cell Neurosci 2019; 13: 133. PubMed PMC

Zhao Y, Zeng CY, Li XH, et al. Klotho overexpression improves amyloid-β clearance and cognition in the APP/PS1 mouse model of Alzheimer’s disease. Aging Cell 2020; 19: 1–17. PubMed PMC

Driscoll I, Betthauser TJ, Gallagher CL, et al. Klotho protein concentrations as a function of sex, APOE, family history or Alzheimer’s disease biomarker status in an at-risk cohort. Alzheimers Dement 2023; 19: e075750.

Ren JR, Wang Z, Cheng Y, et al. Associations between plasma Klotho with renal function and cerebrospinal fluid amyloid-β levels in Alzheimer’s disease: the Chongqing Ageing Dementia Study. J Alzheimers Dis 2023; 92: 477–485. PubMed

Sheardova K, Vyhnalek M, Nedelska Z, et al. Czech Brain Aging Study (CBAS): prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic. BMJ Open 2019; 9: e030379. PubMed PMC

McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263–269. PubMed PMC

Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270–279. PubMed PMC

Jessen F, Amariglio RE, Van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement 2014; 10: 844–852. PubMed PMC

Yesavage JA. Geriatric depression scale. Psychopharmacol Bull 1988; 24: 709–711. PubMed

Fazekas F, Chawluk J, Alavi A, et al. MR Signal abnormalities at 1.5T in Alzheimer’s dementia and normal aging. Am J Roentgenol 1987; 149: 351–356. PubMed

Laczó J, Andel R, Vlček K, et al. Spatial navigation and APOE in amnestic mild cognitive impairment. Neurodegener Dis 2011; 8: 169–177. PubMed

Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545–548. PubMed

Gobom J, Parnetti L, Rosa-Neto P, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med 2022; 60: 207–219. PubMed

Kundu P, Zimmerman B, Perez R, et al. Apolipoprotein E levels in the amygdala and prefrontal cortex predict relative regional brain volumes in irradiated Rhesus macaques. Sci Rep 2021; 11: 22130. PubMed PMC

Bridel C, Somers C, Sieben A, et al. Associating Alzheimer’s disease pathology with its cerebrospinal fluid biomarkers. Brain 2022; 145: 4056–4064. PubMed